Discover how to naturally increase your glutathione levels through diet and lifestyle choices
#ObesityManagement #Semaglutide #Wegovy #HealthcareInnovation #Pharma #PatientCare To view or add a comment, sign in MetaVia's obesity treatment candidate DA-1726 demonstrates weight loss and glycemic control in Phase 1 study MetaVia, an affiliate of Dong-A ST, reported on January 6 that its Phase 1 clinical trial evaluating the maximum tolerated dose of DA-1726(development code), a glucagon-like peptide 1(GLP-1)/glucagon(GCG) dual agonist under development for the treatment of obesity, demonstrated excellent outcomes, including pronounced weight loss, improvements in glycemic control, and a decrease in liver stiffness
Peptide therapy works synergistically with vitamin IV hydration therapy to enhance energy production, support faster recovery, and boost overall health
B.GarverC
The association between OS and RM was also supported by other studies (198, 201, 202)
I was hoping for 15 but 12 is super close